4.6 Article

ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 290, 期 45, 页码 27146-27157

出版社

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M115.665489

关键词

-

资金

  1. Pardee Foundation
  2. National Institutes of Health [T32 CA009357, R01 CA13104505A1, CA17483601A1]
  3. American Society of Clinical Oncology (ASCO) Young Investigator Award
  4. Bladder Cancer Advocacy Network (BCAN) Miriam Gleberman Young Investigator Award

向作者/读者索取更多资源

Background: ATDC/TRIM29 promotes resistance to ionizing radiation, but the factor(s) that mediate this effect are incompletely understood. Results: ATDC/TRIM29 binds to RNF8, promoting DNA repair and resistance to IR. Conclusion: Following DNA damage, ATDC/TRIM29 is phosphorylated and interacts with RNF8, promoting DNA repair and cell survival. Significance: The interaction between ATDC/TRIM29 and RNF8 is novel and is important for the DNA damage response. Induction of DNA damage by ionizing radiation (IR) and/or cytotoxic chemotherapy is an essential component of cancer therapy. The ataxia telangiectasia group D complementing gene (ATDC, also called TRIM29) is highly expressed in many malignancies. It participates in the DNA damage response downstream of ataxia telangiectasia-mutated (ATM) and p38/MK2 and promotes cell survival after IR. To elucidate the downstream mechanisms of ATDC-induced IR protection, we performed a mass spectrometry screen to identify ATDC binding partners. We identified a direct physical interaction between ATDC and the E3 ubiquitin ligase and DNA damage response protein, RNF8, which is required for ATDC-induced radioresistance. This interaction was refined to the C-terminal portion (amino acids 348-588) of ATDC and the RING domain of RNF8 and was disrupted by mutation of ATDC Ser-550 to alanine. Mutations disrupting this interaction abrogated ATDC-induced radioresistance. The interaction between RNF8 and ATDC, which was increased by IR, also promoted downstream DNA damage responses such as IR-induced gamma-H2AX ubiquitination, 53BP1 phosphorylation, and subsequent resolution of the DNA damage foci. These studies define a novel function for ATDC in the RNF8-mediated DNA damage response and implicate RNF8 binding as a key determinant of the radioprotective function of ATDC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell Biology

ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer

Vinee Purohit, Lidong Wang, Huibin Yang, Jiufeng Li, Gina M. Ney, Erica R. Gumkowski, Akash J. Vaidya, Annie Wang, Amit Bhardwaj, Ende Zhao, Igor Dolgalev, Andrea Zamperone, Ethan V. Abel, Marina Pasca Di Magliano, Howard C. Crawford, Daniel Diolaiti, Thales Y. Papagiannakopoulos, Costas A. Lyssiotis, Diane M. Simeone

Summary: The overexpression of ATDC in pancreatic cancer promotes tumor growth and metastasis by protecting cancer cells from ROS through stabilizing NRF2. This mechanism enhances chemoresistance and modulates redox balance in cancer cells.

GENES & DEVELOPMENT (2021)

Editorial Material Oncology

A novel target for combination immunotherapy in pancreatic cancer: IL-1β mediates immunosuppression in the tumour microenvironment

Rafael Winograd, Diane M. Simeone, Dafna Bar-Sagi

Summary: Immune checkpoint blockade has shown efficacy in multiple cancers, but further improvements are needed to increase response rates and achieve clinical efficacy in cold tumors. Mechanistic studies of tumor-specific immunosuppressive pathways can uncover biological barriers to immunotherapy and offer new therapeutic insights.

BRITISH JOURNAL OF CANCER (2021)

Article Oncology

Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma

Jessica N. Everett, Gabriela Burgos, Jennifer Chun, Ariele Baptiste, Lauren G. Khanna, Paul E. Oberstein, Diane M. Simeone

Summary: The study found that surveillance for PDAC is underutilized in high-risk families, with lack of awareness and interest being the primary reasons for nonparticipation. At-risk relatives with familial pancreatic cancer who also carried relevant pathogenic germline variants were more likely to undergo surveillance.

CANCER (2021)

Article Multidisciplinary Sciences

Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis

Yong Xia, Yan Liu, Chao Yang, Diane M. Simeone, Tung-Tien Sun, David J. DeGraff, Moon-shong Tang, Yingkai Zhang, Xue-Ru Wu

Summary: The human chromosome locus 9p21.3 encodes three CDK inhibitors, among which p15INK4B exhibits stronger inhibitory effects on cell cycle and glycolysis compared to p16INK4A, highlighting its significant role as a tumor suppressor in cancer development.

NATURE COMMUNICATIONS (2021)

Editorial Material Gastroenterology & Hepatology

Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Consortium COMMENT

Tamas A. Gonda, Jessica N. Everett, Michael Wallace, Diane M. Simeone

GASTROENTEROLOGY (2021)

Review Cell Biology

The biological underpinnings of therapeutic resistance in pancreatic cancer

Gregory L. Beatty, Gregor Werba, Costas A. Lyssiotis, Diane M. Simeone

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in the United States, with a low survival rate of 10% over 5 years. The disease demonstrates remarkable adaptability and resistance to therapeutic intervention, contributing to its poor prognosis. Recent advances in understanding the biological underpinnings of PDAC have revealed potential vulnerabilities that can be targeted for treatment.

GENES & DEVELOPMENT (2021)

Article Multidisciplinary Sciences

Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer

Annie Wang, Jessica N. Everett, Jennifer Chun, Cindy Cen, Diane M. Simeone, Freya Schnabel

Summary: This study found that breast cancer patients with a family history of pancreatic cancer were more likely to undergo genetic testing, but still a significant proportion did not receive testing or were incompletely tested, suggesting a potential underestimation of pancreatic cancer risk.

SCIENTIFIC REPORTS (2021)

Article Cell Biology

A pan-cancer organoid platform for precision medicine

Brian M. Larsen, Madhavi Kannan, Lee F. Langer, Benjamin D. Leibowitz, Aicha Bentaieb, Andrea Cancino, Igor Dolgalev, Bridgette E. Drummond, Jonathan R. Dry, Chi-Sing Ho, Gaurav Khullar, Benjamin A. Krantz, Brandon Mapes, Kelly E. McKinnon, Jessica Metti, Jason F. Perera, Tim A. Rand, Veronica Sanchez-Freire, Jenna M. Shaxted, Michelle M. Stein, Michael A. Streit, Yi-Hung Carol Tan, Yilin Zhang, Ende Zhao, Jagadish Venkataraman, Martin C. Stumpe, Jeffrey A. Borgia, Ashiq Masood, Daniel V. T. Catenacci, Jeremy Mathews, Demirkan B. Gursel, Jian-Jun Wei, Theodore H. Welling, Diane M. Simeone, Kevin P. White, Aly A. Khan, Catherine Igartua, Ameen A. Salahudeen

Summary: A robust pan-cancer tumor organoid platform with chemically defined media has been established and neural-network-based high-throughput method has been demonstrated to predict patient-specific heterogeneity in drug responses. These resources are expected to accelerate the broad implementation of organoid models in precision medicine research and personalized therapeutic profiling programs.

CELL REPORTS (2021)

Article Gastroenterology & Hepatology

Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium

Tamas A. Gonda, James Farrell, Michael Wallace, Lauren Khanna, Eileen Janec, Richard Kwon, Michael Saunders, Uzma D. Siddiqui, Randall Brand, Diane M. Simeone

Summary: The adoption of a standardized EUS reporting template will improve consistency in clinical decision-making for individuals at risk of pancreatic cancer and provide complete and accurate reporting of pancreatic abnormalities. Standardization will also facilitate research and clinical trial design, allowing for comparison of results across different centers.

GASTROINTESTINAL ENDOSCOPY (2022)

Review Gastroenterology & Hepatology

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment

Laura D. Wood, Marcia Irene Canto, Elizabeth M. Jaffee, Diane M. Simeone

Summary: This review discusses the pathogenesis, early detection methods, and treatment considerations of pancreatic ductal adenocarcinoma (PDAC). Recent advances in understanding PDAC have led to significant improvements in detection and treatment, but coordinated efforts are needed to maximize clinical impact for patients and overall survival.

GASTROENTEROLOGY (2022)

Review Radiology, Nuclear Medicine & Medical Imaging

Standardization of MRI Screening and Reporting in Individuals With Elevated Risk of Pancreatic Ductal Adenocarcinoma: Consensus Statement of the PRECEDE Consortium

Chenchan Huang, Diane M. Simeone, Lyndon Luk, Elizabeth M. Hecht, Gaurav Khatri, Avinash Kambadakone, Hersh Chandarana, Justin M. Ream, Jessica N. Everett, Alexander Guimaraes, Joy Liau, Anil K. Dasyam, Carla Harmath, Alec J. Megibow

Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor survival rates. High-risk individuals are recommended to have regular screening with MRI and/or endoscopic ultrasound. The Pancreatic Cancer Early Detection (PRECEDE) Consortium aims to increase survival of PDAC by facilitating earlier diagnosis through standardized MRI screening and reporting.

AMERICAN JOURNAL OF ROENTGENOLOGY (2022)

Article Biochemistry & Molecular Biology

Functional and biological heterogeneity of KRASQ61 mutations

Minh Huynh, G. Aaron Hobbs, Antje Schaefer, Mariaelena Pierobon, Leiah M. Carey, J. Nathaniel Diehl, Jonathan M. DeLiberty, Ryan D. Thurman, Adelaide R. Cooke, Craig M. Goodwin, Joshua H. Cook, Lin Lin, Andrew M. Waters, Naim U. Rashid, Emanuel F. Petricoin, Sharon L. Campbell, Kevin M. Haigis, Diane M. Simeone, Costas A. Lyssiotis, Adrienne D. Cox, Channing J. Der

Summary: Missense mutations at the three hotspots in RAS-Gly(12), Gly(13), and Gln(61) show differential distribution among the three RAS isoforms. KRAS(Q61) mutants exhibit various changes in morphology, growth transformation, effector signaling, and metabolism. Differences in biochemical, structural, and biological properties may explain the frequency variations. Targeting KRAS(Q61) mutant-specific signaling and cellular output may be a potential therapeutic strategy.

SCIENCE SIGNALING (2022)

Article Oncology

Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting

Jessica N. Everett, Shenin A. Dettwyler, Xiaohong Jing, Cody Stender, Madeleine Schmitter, Ariele Baptiste, Jennifer Chun, Emily A. Kawaler, Lauren G. Khanna, Seth A. Gross, Tamas A. Gonda, Nina Beri, Paul E. Oberstein, Diane M. Simeone

Summary: Integrating genetics into a multidisciplinary setting improves compliance with genetic testing for pancreatic ductal adenocarcinoma (PDAC) patients, reduces logistical barriers, and clarifies cancer risks for relatives.

CANCER MEDICINE (2023)

Article Oncology

DNMT3A/miR-129-2-5p/Rac1 Is an Effector Pathway for SNHG1 to Drive Stem-Cell-like and Invasive Behaviors of Advanced Bladder Cancer Cells

Jiheng Xu, Rui Yang, Jingxia Li, Lidong Wang, Mitchell Cohen, Diane M. Simeone, Max Costa, Xue-Ru Wu

Summary: The stem-cell-like behavior of cancer cells in bladder cancer plays a crucial role and its molecular basis remains incompletely defined. This study demonstrates that SNHG1 induces the formation of stem-cell-like spheres and invasion of bladder cancer cells by upregulating Rho GTPase, Rac1. SNHG1 binds to DNMT3A and represses the transcription of miR-129-2-5p, resulting in increased Rac1 protein levels. High expression of Rac1 is associated with poor prognosis in bladder cancer patients.

CANCERS (2022)

Article Gastroenterology & Hepatology

Proteomes of Extracellular Vesicles From Pancreatic Cancer Cells and Cancer-Associated Fibroblasts

Sharon Pan, Lisa A. Lai, Diane M. M. Simeone, David W. W. Dawson, Yuanqing Yan, Tatjana Crnogorac-Jurcevic, Ru Chen, Teresa A. Brentnall

Summary: Proteomic and functional analysis of extracellular vesicles (EVs) released from pancreatic cancer cells and cancer-associated fibroblasts (CAFs) identified over 1400 nonredundant proteins involved in vesicle-mediated transport and exocytosis. Protein networks relevant to pancreatic tumorigenesis, such as epithelial-mesenchymal transition, complement, and coagulation components, were significantly enriched in EVs from cancer cells or CAFs, suggesting a potential role of EVs in mediating signals related to tumorigenesis and microenvironment interactions.

PANCREAS (2022)

暂无数据